JP2012211150A5 - - Google Patents

Download PDF

Info

Publication number
JP2012211150A5
JP2012211150A5 JP2012128597A JP2012128597A JP2012211150A5 JP 2012211150 A5 JP2012211150 A5 JP 2012211150A5 JP 2012128597 A JP2012128597 A JP 2012128597A JP 2012128597 A JP2012128597 A JP 2012128597A JP 2012211150 A5 JP2012211150 A5 JP 2012211150A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
liquid pharmaceutical
botulinum neurotoxin
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012128597A
Other languages
English (en)
Japanese (ja)
Other versions
JP5662379B2 (ja
JP2012211150A (ja
Filing date
Publication date
Priority claimed from GB0415491A external-priority patent/GB2416122A/en
Application filed filed Critical
Publication of JP2012211150A publication Critical patent/JP2012211150A/ja
Publication of JP2012211150A5 publication Critical patent/JP2012211150A5/ja
Application granted granted Critical
Publication of JP5662379B2 publication Critical patent/JP5662379B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012128597A 2004-07-12 2012-06-06 ボツリヌス神経毒を含む医薬組成物 Expired - Lifetime JP5662379B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0415491A GB2416122A (en) 2004-07-12 2004-07-12 Botulinum neurotoxin composition
GB0415491.0 2004-07-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007520876A Division JP5301830B2 (ja) 2004-07-12 2005-07-06 ボツリヌス神経毒を含む医薬組成物

Publications (3)

Publication Number Publication Date
JP2012211150A JP2012211150A (ja) 2012-11-01
JP2012211150A5 true JP2012211150A5 (enExample) 2014-08-21
JP5662379B2 JP5662379B2 (ja) 2015-01-28

Family

ID=32865775

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007520876A Expired - Lifetime JP5301830B2 (ja) 2004-07-12 2005-07-06 ボツリヌス神経毒を含む医薬組成物
JP2012128597A Expired - Lifetime JP5662379B2 (ja) 2004-07-12 2012-06-06 ボツリヌス神経毒を含む医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007520876A Expired - Lifetime JP5301830B2 (ja) 2004-07-12 2005-07-06 ボツリヌス神経毒を含む医薬組成物

Country Status (19)

Country Link
US (4) US9125804B2 (enExample)
EP (4) EP1817051B2 (enExample)
JP (2) JP5301830B2 (enExample)
CN (2) CN1984675B (enExample)
AR (2) AR049978A1 (enExample)
BR (1) BRPI0513327B8 (enExample)
CA (1) CA2572915C (enExample)
DK (3) DK1817051T4 (enExample)
ES (3) ES2725908T3 (enExample)
FI (1) FI1817051T4 (enExample)
GB (1) GB2416122A (enExample)
HU (2) HUE025434T2 (enExample)
IL (1) IL180380A (enExample)
MX (1) MX2007000409A (enExample)
PL (3) PL2269631T5 (enExample)
PT (3) PT1817051E (enExample)
RU (1) RU2407541C2 (enExample)
TR (1) TR201906275T4 (enExample)
WO (1) WO2006005910A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
KR101284710B1 (ko) 2004-03-03 2013-07-23 레반스 테라퓨틱스, 아이엔씨. 국소 진단제 및 치료제의 수송을 위한 조성물 및 방법
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
CA2599017C (en) 2005-03-03 2014-08-12 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
BRPI0613631A8 (pt) 2005-07-18 2017-12-26 Univ Massachusetts Lowell nanoemulsão e método,
FR2889936B1 (fr) 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AU2016204034B2 (en) * 2005-10-06 2017-12-21 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
PL1959994T3 (pl) 2005-12-01 2018-02-28 University Of Massachusetts Lowell Nanoemulsje botulinowe
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
JP2010528981A (ja) 2006-12-01 2010-08-26 アンテリオス， インコーポレイテッド 両親媒性実体ナノ粒子
US20100172943A1 (en) 2006-12-01 2010-07-08 Anterios, Inc. Peptide nanoparticles and uses therefor
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
KR20100050443A (ko) 2007-05-31 2010-05-13 안테리오스, 인코퍼레이티드 핵산 나노입자 및 이의 용도
ES2391798T3 (es) 2007-07-10 2012-11-30 Medy-Tox, Inc. Composición líquida farmacéutica de toxina botulínica con estabilidad mejorada
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
WO2009158687A1 (en) * 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
CN102307571A (zh) * 2008-12-10 2012-01-04 阿勒根公司 梭菌毒素药物组合物
EP3332805B1 (en) 2008-12-31 2022-02-23 ReVance Therapeutics, Inc. Injectable botulinum toxin formulations
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
AU2010265888A1 (en) 2009-06-25 2012-01-19 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
AU2011316111B2 (en) 2010-10-12 2015-05-28 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
DK3241547T3 (da) * 2011-03-31 2020-08-17 Medy-Tox Inc Lyofiliseret præparat af botulinumtoksin
US9498521B2 (en) * 2011-09-28 2016-11-22 Wisconsin Alumni Research Foundation Purification, characterization, and use of Clostridium botulinum neurotoxin BoNT/A3
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
JP2015534814A (ja) * 2012-10-31 2015-12-07 イプセン バイオイノベーション リミテッド 組換えクロストリジウムボツリヌス神経毒
WO2014145735A2 (en) 2013-03-15 2014-09-18 Orpro Therapeutics, Inc. Product and process for mucus viscosity normalization
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
RU2593344C2 (ru) * 2014-03-05 2016-08-10 Михаил Григорьевич Сойхер Способ лечения бруксизма
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
KR102557798B1 (ko) 2014-12-23 2023-07-19 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소 사전충전된 용기
AR103244A1 (es) * 2015-02-03 2017-04-26 Merz Pharma Gmbh & Co Kgaa Recipiente precargado con toxina botulínica
ES2907652T3 (es) 2015-10-29 2022-04-25 Revance Therapeutics Inc Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen un efecto terapéutico o cosmético de larga duración
WO2017177160A1 (en) 2016-04-07 2017-10-12 Nevakar Llc Formulation for use in a method of treatment of pain
RU2741497C9 (ru) 2016-05-27 2021-04-30 Ипсен Биофарм Лимитед Жидкая композиция нейротоксина, стабилизированная триптофаном или тирозином
RU2651044C2 (ru) * 2016-08-22 2018-04-18 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ им. ак. Е.Н. Мешалкина" Минздрава России) Способ лечения желудочковых нарушений ритма сердца (варианты)
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
PL3432916T3 (pl) 2016-09-13 2020-04-30 Allergan, Inc. Niebiałkowo stabilzowane kompozycje toksyny clostridium
BR112019010131A2 (pt) 2016-11-21 2019-10-08 Eirion Therapeutics Inc entrega transdérmica de agentes grandes
KR101744900B1 (ko) * 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
BR112019017001A2 (pt) 2017-02-16 2020-04-28 Sonnet Bio Therapeutics composição, proteína de fusão, ácido nucleico, célula hospedeira, e, métodos para produção de um domínio de aglutinação de albumina, para preparação de uma variante de il-15, para produção de uma proteína de fusão e para inibição ou redução de um tumor em um indivíduo em necessidade do mesmo.
WO2019070641A1 (en) * 2017-10-03 2019-04-11 Nevakar Inc. COMBINATIONS OF ACETAMINOPHENE-PRÉGABALINE AND METHODS OF TREATING PAIN
WO2019113044A1 (en) * 2017-12-07 2019-06-13 Ps Therapies Ltd Topical compositions and methods of use thereof
CN113573727A (zh) * 2019-02-21 2021-10-29 梅尔兹制药公司 肉毒神经毒素用于治疗震颤的新用途
RU2728102C1 (ru) * 2019-12-19 2020-07-28 Александр Александрович Ильин Способ лечения гипертонуса латеральной крыловидной мышцы
KR102324855B1 (ko) * 2020-05-20 2021-11-11 오스템임플란트 주식회사 보툴리눔 독소를 포함하는 약제학적 액상 조성물
JP2024500416A (ja) * 2020-12-18 2024-01-09 エーティージーシー カンパニー、リミテッド ボツリヌス毒素の液剤を長期保管するための薬学的組成物
CN119258202A (zh) * 2023-07-05 2025-01-07 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物及其应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US20030095927A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
JP2002501033A (ja) 1998-01-26 2002-01-15 ユニバーシティー オブ マサチューセッツ Ａ型ボツリヌス菌の生物学的活性赤血球凝集素とその使用法
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
CN1258379C (zh) 2000-02-08 2006-06-07 阿勒根公司 肉毒杆菌毒素药物组合物
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
AU2002320127A1 (en) * 2001-06-21 2003-01-08 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
US20030224020A1 (en) * 2002-05-31 2003-12-04 Zabudkin Alexander F. Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
RU2206337C1 (ru) * 2002-10-29 2003-06-20 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Лекарственный препарат для лечения мышечных дистоний и способ его получения
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
PT2813239T (pt) 2004-08-04 2017-06-09 Ipsen Biopharm Ltd Composição farmacêutica contendo a neurotoxina botulínica a2
WO2006013370A1 (en) * 2004-08-04 2006-02-09 Ipsen Limited Pharmaceutical composition containing botulinum neurotoxin a2
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions

Similar Documents

Publication Publication Date Title
JP2012211150A5 (enExample)
ECSP23041058A (es) Formulación subcutánea de anticuerpo anti-her2
JP2017516848A5 (enExample)
JP2017516847A5 (enExample)
IL259921A (en) A new stabilizing factor for pharmaceutical proteins
WO2015044292A8 (en) Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
MX2012002861A (es) Formulaciones farmaceuticas muy concentradas.
JP2016065060A5 (enExample)
JP2013505270A5 (enExample)
FI2504353T4 (fi) Lipopeptidikoostumukset ja vastaavat menetelmät
JP2012515221A5 (enExample)
JP2013543505A5 (enExample)
AR081679A1 (es) Metodos y composiciones para la administracion intratecal de heparan n-sulfatasa, envase
NZ725360A (en) Liquid pharmaceutical composition
HRP20201242T1 (hr) Tekući farmaceutski pripravak
BR112016006455A2 (pt) ?formulação de conjugado de hormônio de crescimento humano de ação prolongada?
BR112015008815A2 (pt) variantes do receptor iib de fc gama
JP2014516515A5 (enExample)
CN104507495A (zh) 轮状病毒疫苗组合物及其制备方法
FI3554474T3 (fi) Mikafungiinikoostumuksia
AR086672A1 (es) Formulaciones de furina recombinante
JP2018522894A5 (enExample)
CR20200240A (es) Formulación farmacéutica estable de una proteína de fusión
TH138064A (th) สูตรตำรับแอนทิบอดีแอนทิ-her2 ใต้หนัง
Pandeya et al. Expression and purification of a functional human hepatitis B virus polymerase